Literature DB >> 32092638

Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases.

Xiaojiaoyang Li1, Junde Ge2, Qi Zheng3, Jiaxiang Zhang2, Rong Sun4, Runping Liu5.   

Abstract

BACKGROUND: Liver is the pivotal organ responsible for plasma protein production, biliary secretion, xenobiotic elimination, glucose and lipid homeostasis. Dysregulation of these functions usually leads to liver diseases and further related complications. The incidence of liver diseases is increasing worldwide, with high morbidity and mortality when at advanced stages, and has become significant public health concern and substential economic burden. Thus, novel therapeutic strategies for managing liver diseases progression are urgently required. T. ruticarpum is one of the most famous and frequently used herbal medicine and has been prescribed in traditional Chinese medicine (TCM) formulas for the treatment of various ailments, including liver diseases. A considerable amount of bioactive ingredients have been isolated and identified from the roots of T. ruticarpum, including alkaloids, saponins, phenols, volatile oils and other compounds. Among these compounds, evodiamine (EVO) and rutaecarpine (RUT) are believed to be the most bioactive compounds.
PURPOSE: To summarize recent findings regarding to the metabolism, pharmacological/toxicological effects of EVO and RUT and to highlight the potential therapeutic effects of them against liver diseases.
METHODS: Online academic databases (including PubMed, Google Scholar, Web of Science and CNKI) were searched using search terms of "T. ruticarpum", "Wu Zhu Yu", "evodiamine", "rutaecarpine", "liver" and combinations to include published studies of EVO and RUT primarily from 2004-2019. Several critical previous studies beyond this period were also included.
RESULTS: Evodiamine (EVO) and rutaecarpine (RUT) are believed to be the most bioactive alkaloids in T. ruticarpum, having anti-inflammation, anti-fibrosis, anti-lipotoxicity, anti-cancer activities, and thus having potential to improve liver disorders. In the current review, we comprehensively summarized recent progresses in the studies of EVO- and RUT-mediated promising hepatoprotective effects and also provide novel insights regarding the potential use of EVO and RUT as therapeutic options for the treatment of liver diseases.
CONCLUSION: With further in-depth pharmacology and pharmacokinetic studies, we believe that natural products in T. ruticarpum and their derivatives will become promising medicines with improved clinical efficacy for the treatment of liver diseases in the immediate future.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Evodiamine; Liver diseases; Rutaecarpine

Year:  2020        PMID: 32092638     DOI: 10.1016/j.phymed.2020.153180

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  11 in total

1.  Upregulation of SIRT1 by Evodiamine activates PI3K/AKT pathway and blocks intervertebral disc degeneration.

Authors:  Jianbo Kuai; Na Zhang
Journal:  Mol Med Rep       Date:  2022-06-28       Impact factor: 3.423

2.  The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats.

Authors:  Yufan Dai; Wenyu Zhu; Jiaxuan Zhou; Tao Shen
Journal:  Braz J Med Biol Res       Date:  2022-05-16       Impact factor: 2.904

3.  Rutaecarpine suppresses the proliferation and metastasis of colon cancer cells by regulating the STAT3 signaling.

Authors:  Shixin Chan; Rui Sun; Xucan Tu; Manyu Guo; Qianqian Yuan; Zhen Yu; Zhenglin Wang; Shaocheng Hong; Wei Han; Bingbing Zou; Zeng Li; Huabing Zhang; Wei Chen
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

Review 4.  Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis.

Authors:  Rui Qin; Qian Zhao; Bo Han; Hong-Ping Zhu; Cheng Peng; Gu Zhan; Wei Huang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

5.  The Anti-Proliferative and Apoptotic Effects of Rutaecarpine on Human Esophageal Squamous Cell Carcinoma Cell Line CE81T/VGH In Vitro and In Vivo.

Authors:  Li-Yu Wang; Shu-Lan Yeh; Shih-Tien Hsu; Chao-Hsiang Chen; Chien-Chih Chen; Cheng-Hung Chuang
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

Review 6.  Traditional Chinese medicine: An important source for discovering candidate agents against hepatic fibrosis.

Authors:  Wen-Qing Li; Wen-Hao Liu; Die Qian; Jia Liu; Shi-Qiong Zhou; Lei Zhang; Wei Peng; Li Su; Hong Zhang
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

7.  Simultaneous LC-MS/MS bioanalysis of alkaloids, terpenoids, and flavonoids in rat plasma through salting-out-assisted liquid-liquid extraction after oral administration of extract from Tetradium ruticarpum and Glycyrrhiza uralensis: a sample preparation strategy to broaden analyte coverage of herbal medicines.

Authors:  Manlin Li; Hanxue Wang; Xiaohan Huan; Ning Cao; Huida Guan; Hongmei Zhang; Xuemei Cheng; Changhong Wang
Journal:  Anal Bioanal Chem       Date:  2021-07-31       Impact factor: 4.142

8.  Hepatotoxic effects of melamine exposure from the weaning period in rats: a flow cytometric, electron microscopic, and histopathologic study.

Authors:  Zuleyha Erisgin; Hasan Serdar Mutlu; Yavuz Tekelioglu; Engin Deveci; Ugur Seker
Journal:  Toxicol Res (Camb)       Date:  2021-04-26       Impact factor: 3.524

9.  An ethnoveterinary study on medicinal plants used by the Buyi people in Southwest Guizhou, China.

Authors:  Yong Xiong; Chunlin Long
Journal:  J Ethnobiol Ethnomed       Date:  2020-08-17       Impact factor: 2.733

10.  Rutaecarpine Inhibits U87 Glioblastoma Cell Migration by Activating the Aryl Hydrocarbon Receptor Signaling Pathway.

Authors:  Yiyun Liu; Yangsheng Chen; Ruihong Zhu; Li Xu; Heidi Qunhui Xie; Bin Zhao
Journal:  Front Mol Neurosci       Date:  2021-12-09       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.